• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Dow Turns Lower; ISM Services PMI Falls In December

    1/5/24 12:11:05 PM ET
    $AGL
    $APLT
    $DRMA
    $MPW
    Misc Health and Biotechnology Services
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AGL alert in real time by email

    U.S. stocks traded mixed midway through trading, with the Dow Jones index falling around 70 points on Friday.

    The Dow traded down 0.19% to 37,369.52 while the NASDAQ rose 0.16% to 14,533.16. The S&P 500 also rose, gaining, 0.12% to 4,694.09.

    Check This Out: Cramer Says This 'Inexpensive' Stock Is 'Doing Some Great Things With Aerospace'

     

    Leading and Lagging Sectors

     

    Consumer discretionary shares jumped by 0.9% on Friday.

    In trading on Friday, health care shares rose by just 0.1%.

     

    Top Headline

     

    The ISM services PMI declined to 50.6 in December, recording the weakest reading in seven months, versus November’s reading of 52.7.

     

    Equities Trading UP

     

    Dermata Therapeutics, Inc. (NASDAQ:DRMA) shares shot up 24% to $0.7593 after the company announced the issuance of a new patent in Japan for its DMT410 program for hyperhidrosis (excessive sweating that's not always related to heat or exercise).

    Shares of Banzai International, Inc. (NASDAQ:BNZI) got a boost, surging 94% to $3.2141. Banzai International signed a non-binding letter of intent to acquire IGLeads, a cutting-edge automated lead generation platform.

    Revelstone Capital Acquisition Corp. (NASDAQ:RCAC) shares were also up, gaining 90% to $10.74. Revelstone Capital Acquisition cancelled special meeting to approve business combination with Set Jet, Inc.

     

    Equities Trading DOWN

     

    Applied Therapeutics, Inc. (NASDAQ:APLT) shares dropped 35% to $2.4750 after the company released topline results of the ARISE-HF Phase 3 trial of AT-001 (caficrestat) in patients with Diabetic Cardiomyopathy (DbCM) at high risk of progression to overt heart failure.

    Shares of agilon health, inc. (NYSE:AGL) were down 36% to $7.70 after the company lowered its 2023 financial outlook.

    Medical Properties Trust, Inc. (NYSE:MPW) was down, falling 31% to $3.4650 after it disclosed plans to reduce its exposure to tenant Steward Health Care System. Keybanc analyst Austin Wurschmidt downgraded Medical Properties Trust from Overweight to Sector Weight.

    Also Check This Out: Beat Inflation With These 3 High-Yielding Dividend Stocks In Tech And Telecom Sector From Wall Street's Most Accurate Analysts

     

    Commodities

     

    In commodity news, oil traded up 2.2% to $73.79 while gold traded up 0.9% at $2,068.40.

    Silver traded up 1.9% to $23.635 on Friday while copper rose 0.2% to $3.8525.

     

    Euro zone

     

    European shares were mostly lower today. The eurozone’s STOXX 600 fell 0.24%, London’s FTSE 100 fell 0.41% while Spain’s IBEX 35 Index fell 0.07% The German DAX rose 0.01% French CAC 40 fell 0.33% while Italy’s FTSE MIB Index rose 0.19%.

    Industrial producer prices in the Eurozone declined 8.8% year-over-year in November versus a 9.4% decline a month ago. The inflation rate in the Eurozone increased to 2.9% year-over-year in December versus an over two-year low level of 2.4% in November. The HCOB Eurozone Construction PMI rose to 43.6 in December versus 43.4 a month ago.

    The S&P Global UK construction PMI rose to 46.8 in December from 45.5 in November, while Halifax House Price Index increased by 1.7% year-over-year in December. French construction PMI declined to 42.6 in December from 44.6 in November, while HCOB Germany construction PMI rose to 37 in December from 36.2 in the prior month.

     

    Asia Pacific Markets

     

    Asian markets closed mixed on Friday, with Japan’s Nikkei 225 gaining 0.27%, Hong Kong’s Hang Seng Index falling 0.66% and China’s Shanghai Composite Index falling 0.85%. India’s S&P BSE Sensex, meanwhile, rose 0.25%.

    Foreign exchange reserves in Hong Kong rose to $425.5 billion in December versus a seven-month high level of $424.6 billion a month ago. The S&P Global Indian services PMI climbed to 59.0 in December versus 56.9 a month ago. The consumer confidence index in Japan climbed to 37.2 in December from 36.1 in the previous month, while Japanese services PMI was revised lower to 51.5 in December versus preliminary reading of 52.0.

     

    Economics

     

    The U.S. economy added 216,000 jobs in December versus a revised 173,000 in November, and compared to market estimates of 170,000.

    The unemployment rate in the U.S. came in unchanged at 3.7% in December, compared to market estimates of 3.8%.

    Average hourly earnings for all employees on US private nonfarm payrolls increased by 0.4% over a month to $34.27 for December.

    The ISM services PMI declined to 50.6 in December, recording the weakest reading in seven months, versus November’s reading of 52.7.

    U.S. factory orders rose 2.6% month-over-month in November versus a revised 3.4% decline in October.

    Now Read This: Alphabet, Kraft Heinz And 2 Other Stocks Insiders Are Selling

    Get the next $AGL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AGL
    $APLT
    $DRMA
    $MPW

    CompanyDatePrice TargetRatingAnalyst
    Applied Therapeutics Inc.
    $APLT
    12/12/2025Outperform → Neutral
    Robert W. Baird
    Applied Therapeutics Inc.
    $APLT
    12/3/2025$1.00Outperform → Market Perform
    Leerink Partners
    agilon health inc.
    $AGL
    8/20/2025$1.40Outperform → Mkt Perform
    Bernstein
    agilon health inc.
    $AGL
    8/6/2025$1.00Buy → Neutral
    Citigroup
    agilon health inc.
    $AGL
    4/25/2025$5.00Neutral → Buy
    Citigroup
    agilon health inc.
    $AGL
    4/8/2025$8.50Mkt Perform → Outperform
    Bernstein
    Medical Properties Trust Inc.
    $MPW
    3/12/2025$5.00 → $9.00Neutral → Outperform
    Exane BNP Paribas
    agilon health inc.
    $AGL
    1/10/2025$1.75 → $2.25Sell → Neutral
    Citigroup
    More analyst ratings

    $AGL
    $APLT
    $DRMA
    $MPW
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Dermata Therapeutics Inc.

    SCHEDULE 13G/A - Dermata Therapeutics, Inc. (0001853816) (Subject)

    2/9/26 5:45:18 PM ET
    $DRMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by Applied Therapeutics Inc.

    EFFECT - Applied Therapeutics, Inc. (0001697532) (Filer)

    2/9/26 12:15:09 AM ET
    $APLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by Applied Therapeutics Inc.

    EFFECT - Applied Therapeutics, Inc. (0001697532) (Filer)

    2/9/26 12:15:13 AM ET
    $APLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGL
    $APLT
    $DRMA
    $MPW
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Kanter Stacy J. returned 22,500 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - Applied Therapeutics, Inc. (0001697532) (Issuer)

    2/4/26 11:17:54 AM ET
    $APLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Commercial Officer Hooks Corwin Dale was granted 312,500 shares and returned 862,500 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - Applied Therapeutics, Inc. (0001697532) (Issuer)

    2/3/26 7:16:05 PM ET
    $APLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Officer Chinoporos Constantine was granted 437,500 shares and returned 1,000,000 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - Applied Therapeutics, Inc. (0001697532) (Issuer)

    2/3/26 7:03:25 PM ET
    $APLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGL
    $APLT
    $DRMA
    $MPW
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Applied Therapeutics downgraded by Robert W. Baird

    Robert W. Baird downgraded Applied Therapeutics from Outperform to Neutral

    12/12/25 9:22:39 AM ET
    $APLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Applied Therapeutics downgraded by Leerink Partners with a new price target

    Leerink Partners downgraded Applied Therapeutics from Outperform to Market Perform and set a new price target of $1.00

    12/3/25 8:27:30 AM ET
    $APLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Agilon Health downgraded by Bernstein with a new price target

    Bernstein downgraded Agilon Health from Outperform to Mkt Perform and set a new price target of $1.40

    8/20/25 8:21:47 AM ET
    $AGL
    Misc Health and Biotechnology Services
    Health Care

    $AGL
    $APLT
    $DRMA
    $MPW
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Wulf John William bought $50,941 worth of shares (81,000 units at $0.63), increasing direct ownership by 28% to 365,857 units (SEC Form 4)

    4 - agilon health, inc. (0001831097) (Issuer)

    1/30/26 7:30:58 PM ET
    $AGL
    Misc Health and Biotechnology Services
    Health Care

    Amendment: Chief Financial Officer Schwaneke Jeffrey A. bought $250,206 worth of shares (22,300 units at $11.22) and was granted 428,922 shares, increasing direct ownership by 61% to 1,130,552 units (SEC Form 4)

    4/A - agilon health, inc. (0001831097) (Issuer)

    4/3/25 7:40:25 PM ET
    $AGL
    Misc Health and Biotechnology Services
    Health Care

    CEO & President Sell Steven covered exercise/tax liability with 15,563 shares and bought 42,426 shares, increasing direct ownership by 8% to 355,310 units (SEC Form 4)

    4 - agilon health, inc. (0001831097) (Issuer)

    3/18/25 6:42:37 PM ET
    $AGL
    Misc Health and Biotechnology Services
    Health Care

    $AGL
    $APLT
    $DRMA
    $MPW
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cycle Pharmaceuticals Completes Acquisition of Applied Therapeutics

    Cycle Group Holdings Limited ("Cycle") is delighted to announce it has completed the acquisition of NASDAQ-listed Applied Therapeutics, Inc. (NASDAQ:APLT, "Applied")), a clinical-stage biopharmaceutical company. Applied's lead drug candidate, govorestat, is a novel central nervous system (CNS) penetrant Aldose Reductase Inhibitor (ARI) for the treatment of CNS rare metabolic diseases, including Classic Galactosemia, Charcot-Marie-Tooth Sorbitol Dehydrogenase Deficiency (CMT-SORD) and phosphomannomutase 2 congenital disorder of glycosylation (PMM2-CDG), for which there are currently no FDA approved treatment options available. "Cycle was founded with a commitment to support patients livi

    2/3/26 8:39:00 AM ET
    $APLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Applied Therapeutics Shares Letter to Stockholders Recommending Tender of Shares Following Offer Expiration Extension

    NEW YORK, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ:APLT) (the "Company" or "Applied"), a clinical-stage biopharmaceutical company dedicated to creating transformative treatments for rare diseases, today released the following letter to stockholders regarding the pending tender offer by AT2B, Inc. ("Purchaser"), an indirect wholly owned subsidiary of Cycle Group Holdings Limited ("Cycle"). January 29, 2026 Dear Applied Therapeutics Stockholders, As announced on December 11, 2025, we entered into a definitive agreement (the "Merger Agreement") with Cycle, a United Kingdom-based company focused on rare genetic conditions in metabolic, immunology, urology and onc

    1/29/26 8:15:13 AM ET
    $APLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    agilon health Sets Date to Report Fourth Quarter and Full Year 2025 Financial Results

    agilon health, inc. (NYSE:AGL), the trusted partner empowering physicians to transform health care in our communities, today announced that it will release financial results for the fourth quarter and full year 2025 after market close on Wednesday, February 25, 2026 and host a conference call at 4:30 p.m. ET to discuss the results. The conference call can be accessed by dialing (833) 470-1428 for U.S. participants and +1 (404) 975-4839 for international participants and referencing participant code 868078. A simultaneous webcast can be accessed by visiting the "Events & Presentations" section of agilon's Investor Relations website at https://investors.agilonhealth.com. A replay of the cal

    1/22/26 4:05:00 PM ET
    $AGL
    Misc Health and Biotechnology Services
    Health Care

    $AGL
    $APLT
    $DRMA
    $MPW
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Applied Therapeutics Inc.

    SC 13G/A - Applied Therapeutics, Inc. (0001697532) (Subject)

    11/14/24 5:47:55 PM ET
    $APLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Dermata Therapeutics Inc.

    SC 13G/A - Dermata Therapeutics, Inc. (0001853816) (Subject)

    11/14/24 5:07:13 PM ET
    $DRMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Applied Therapeutics Inc.

    SC 13G/A - Applied Therapeutics, Inc. (0001697532) (Subject)

    11/14/24 4:50:26 PM ET
    $APLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGL
    $APLT
    $DRMA
    $MPW
    Leadership Updates

    Live Leadership Updates

    View All

    National Healthcare Properties Announces Andrew T. Babin as Chief Financial Officer

    NEW YORK, Nov. 18, 2025 (GLOBE NEWSWIRE) -- National Healthcare Properties, Inc. (NASDAQ:NHPAP) ("NHP") announced today the appointment of Andrew T. Babin as Chief Financial Officer and Treasurer effective on November 18, 2025, following the resignation of Scott M. Lappetito, who has resigned effective as of such date to pursue other opportunities. "We are pleased to welcome Drew to National Healthcare Properties," stated Michael Anderson, Chief Executive Officer and President. "Drew has long demonstrated success across senior buy-side, sell-side and corporate roles throughout his career and brings with him financial, capital markets and investor relations expertise and strong relationshi

    11/18/25 4:30:00 PM ET
    $MPW
    Real Estate Investment Trusts
    Real Estate

    Applied Therapeutics Reports Third Quarter 2025 Financial Results

    –   Update on regulatory strategy for govorestat for the treatment of CMT-SORD following receipt of Type C meeting minutes –   Meeting scheduled with the FDA in 4Q 2025 to discuss govorestat for the treatment of Classic Galactosemia –   New data on govorestat for the treatment of PMM2-CDG published in JIMD and presented at the 2025 ASHG Annual Meeting –   Announces Board of Directors Leadership Transition NEW YORK, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ:APLT) (the "Company"), a clinical-stage biopharmaceutical company dedicated to creating transformative treatments for rare diseases, today reported financial results for the third quarter ended September 30

    11/13/25 7:00:00 AM ET
    $APLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    agilon health Announces Leadership Transition

    Steven Sell steps down as President, Chief Executive Officer, and Board Director Ronald A. Williams, co-founder, Board Chairman, and healthcare industry veteran, appointed Executive Chairman Board establishes an Office of the Chairman and initiates search for permanent CEO Company reports second quarter 2025 earnings and withdraws full year 2025 guidance agilon health (NYSE:AGL), the trusted partner empowering physicians to transform health care in our communities, announced today that Steven Sell has stepped down as President, CEO, and a Director of the Board. Ronald A. Williams, the Company's co-founder and Board Chairman since 2017, has been appointed Executive Chairman. Williams

    8/4/25 4:10:00 PM ET
    $AGL
    Misc Health and Biotechnology Services
    Health Care

    $AGL
    $APLT
    $DRMA
    $MPW
    Financials

    Live finance-specific insights

    View All

    Cycle Pharmaceuticals Completes Acquisition of Applied Therapeutics

    Cycle Group Holdings Limited ("Cycle") is delighted to announce it has completed the acquisition of NASDAQ-listed Applied Therapeutics, Inc. (NASDAQ:APLT, "Applied")), a clinical-stage biopharmaceutical company. Applied's lead drug candidate, govorestat, is a novel central nervous system (CNS) penetrant Aldose Reductase Inhibitor (ARI) for the treatment of CNS rare metabolic diseases, including Classic Galactosemia, Charcot-Marie-Tooth Sorbitol Dehydrogenase Deficiency (CMT-SORD) and phosphomannomutase 2 congenital disorder of glycosylation (PMM2-CDG), for which there are currently no FDA approved treatment options available. "Cycle was founded with a commitment to support patients livi

    2/3/26 8:39:00 AM ET
    $APLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    agilon health Sets Date to Report Fourth Quarter and Full Year 2025 Financial Results

    agilon health, inc. (NYSE:AGL), the trusted partner empowering physicians to transform health care in our communities, today announced that it will release financial results for the fourth quarter and full year 2025 after market close on Wednesday, February 25, 2026 and host a conference call at 4:30 p.m. ET to discuss the results. The conference call can be accessed by dialing (833) 470-1428 for U.S. participants and +1 (404) 975-4839 for international participants and referencing participant code 868078. A simultaneous webcast can be accessed by visiting the "Events & Presentations" section of agilon's Investor Relations website at https://investors.agilonhealth.com. A replay of the cal

    1/22/26 4:05:00 PM ET
    $AGL
    Misc Health and Biotechnology Services
    Health Care

    Medical Properties Trust Increases Regular Quarterly Dividend

    Board of Directors declares quarterly dividend of $0.09 per common share, an increase of 12% from last quarter Medical Properties Trust, Inc. (the "Company" or "MPT") (NYSE:MPW) today announced that its Board of Directors declared a regular quarterly cash dividend of $0.09 per share of common stock to be paid on January 8, 2026, to stockholders of record on December 11, 2025. Edward K. Aldag, Jr., Chairman, President, and Chief Executive Officer, said, "This dividend increase reflects our growing confidence in the strength of our portfolio and cash flow potential in the year ahead. Together with our recently announced $150 million common stock repurchase program, we are well positioned

    11/17/25 8:30:00 AM ET
    $MPW
    Real Estate Investment Trusts
    Real Estate